List view / Grid view
Rachael Harper (European Pharmaceutical Review)
Filter the results
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
Compounded drug products are being voluntarily recalled due a lack of sterility assurance.
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
The Secretary of State for Health and Social Care is supporting the continuity of medical supplies if the UK is to leave the EU without a deal.
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
A new cell therapy has been tested in patients with liver cirrhosis and found no significant adverse effects.
The FDA has approved the first treatment to increase pain-free light exposure in patients with the rare disorder, erythropoietic protoporphyria.
A drug capsule that can carry insulin and protect them from the harsh environment of the gastrointestinal tract has been developed.
Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue's bankruptcy, it has been reported.
Rituxan (rituximab) is the first approved treatment for children with rare vasculitis diseases, in which a patient’s small blood vessels become inflamed.
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
King Pharmaceuticals Limited and Alissa Healthcare Research Limited have admitted to sharing information to keep drug prices up.
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.